Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Chambers

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Health Affairs Scholar|February 25, 2026
The timeliness of health plan drug coverage policy changes to FDA label revisionsDaniel E Enright, Molly T Beinfeld, Claire H Brennan, et al.
Journal of Managed Care & Specialty Pharmacy|June 2, 2024
US commercial health plan coverage dynamics in pulmonary arterial hypertension therapiesJulia A Rucker, Molly T Beinfeld, Daniel E Enright, et al.
Journal of Managed Care & Specialty Pharmacy|February 4, 2026
Use of clinical outcome assessments in specialty drug coverage policiesJulia A Rucker, Jiat Ling Poon, Fariel C A LaMountain, et al.
Journal of Managed Care & Specialty Pharmacy|August 31, 2021
Variation in health plan coverage of ESAs for anemia due to chronic kidney diseaseNikoLetta M Margaretos, Ari D Panzer, Rachel C Lai, et al.
Journal of General Internal Medicine|February 23, 2021
An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence ConsideredDavid D Kim, Lauren A Do, Allan T Daly, et al.
Plos One|April 30, 2015
An assessment of the methodological quality of published network meta-analyses: a systematic reviewJames D Chambers, Huseyin Naci, Olivier J Wouters, et al.
Plos One|July 22, 2015
Correction: An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic ReviewJames D Chambers, Huseyin Naci, Olivier J Wouters, et al.
Journal of Oncology Practice|June 11, 2015
How Do Payers Respond to Regulatory Actions? The Case of BevacizumabStacie B Dusetzina, Shellie Ellis, Rachel A Freedman, et al.
Health Policy (Amsterdam, Netherlands)|November 12, 2021
Variation in market access decisions for cell and gene therapies across the United States, Canada, and EuropeSean Tunis, Eve Hanna, Peter J Neumann, et al.
Health Affairs (Project Hope)|September 6, 2022
State-Level Variation In Low-Value Care For Commercially Insured And Medicare Advantage PopulationsLauren A Do, Benjamin C Koethe, Allan T Daly, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Health Affairs Scholar|February 25, 2026
The timeliness of health plan drug coverage policy changes to FDA label revisionsDaniel E Enright, Molly T Beinfeld, Claire H Brennan, et al.
Journal of Managed Care & Specialty Pharmacy|June 2, 2024
US commercial health plan coverage dynamics in pulmonary arterial hypertension therapiesJulia A Rucker, Molly T Beinfeld, Daniel E Enright, et al.
Journal of Managed Care & Specialty Pharmacy|February 4, 2026
Use of clinical outcome assessments in specialty drug coverage policiesJulia A Rucker, Jiat Ling Poon, Fariel C A LaMountain, et al.
Journal of Managed Care & Specialty Pharmacy|August 31, 2021
Variation in health plan coverage of ESAs for anemia due to chronic kidney diseaseNikoLetta M Margaretos, Ari D Panzer, Rachel C Lai, et al.
Journal of General Internal Medicine|February 23, 2021
An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence ConsideredDavid D Kim, Lauren A Do, Allan T Daly, et al.
Plos One|April 30, 2015
An assessment of the methodological quality of published network meta-analyses: a systematic reviewJames D Chambers, Huseyin Naci, Olivier J Wouters, et al.
Plos One|July 22, 2015
Correction: An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic ReviewJames D Chambers, Huseyin Naci, Olivier J Wouters, et al.
Journal of Oncology Practice|June 11, 2015
How Do Payers Respond to Regulatory Actions? The Case of BevacizumabStacie B Dusetzina, Shellie Ellis, Rachel A Freedman, et al.
Health Policy (Amsterdam, Netherlands)|November 12, 2021
Variation in market access decisions for cell and gene therapies across the United States, Canada, and EuropeSean Tunis, Eve Hanna, Peter J Neumann, et al.
Health Affairs (Project Hope)|September 6, 2022
State-Level Variation In Low-Value Care For Commercially Insured And Medicare Advantage PopulationsLauren A Do, Benjamin C Koethe, Allan T Daly, et al.
Pageof 9